Elbow arthritis is a common cause of forelimb lameness and disability in dogs of all ages; the primary cause being a developmental disease called ‘elbow dysplasia’. Management of this arthritis usually consists chronic administration of drugs (e.g. non-steroidal anti-inflammatories such as carprofen), weight management, supplements, and appropriate exercise. Despite all these interventions, many dogs continue to display lameness of the forelimbs. Librela™ (bedinvetmab) is a new monthly injectable medication available for the treatment of dogs with arthritis. It is a monoclonal antibody that targets a nerve growth factor that contributes to the pain associated with arthritis. Company provided data shows that dogs seem to improve with administration of the medication. We aim to discover the degree and duration of improvement associated with this medication by collecting functional gait data over the course of 6 months of medication administration and comparing this to the same data in untreated dogs.